Login Register Cart 0
Generic placeholder image

Current Drug Delivery

Editor-in-Chief

ISSN (Print): 1567-2018
ISSN (Online): 1875-5704

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Abuse-Deterrent Formulations in Constraining the Abuse Potential of Prescription Medicines: A Myth or Truth

Author(s): Parmita Phaugat*, Suchitra Nishal and Rakhi Dhiman

Volume 19, Issue 4, 2022

Published on: 06 January, 2022

Page: [466 - 478] Pages: 13

DOI: 10.2174/1567201818666210805145819

Price: $65

Abstract

Background: Diverse pain killers used for the management of varied categories of pain are being misused in order to have extreme pleasant effects by a large number of populations. To overcome the misuse of prescription drugs, regulatory bodies have given stress on the development of abuse resistance.

Methods: We studied numerous literatures: (1) Research and review papers including the guidelines for pain management, abuse, and abuse deterrence; (2) Description and categorization of pain along with the management approaches; (3) Advantages and disadvantages of the abuse-deterrent formulations.

Results: Abuse-deterrent formulations are the contemporary remedial treatment for pain with reduced prospects of being abused. But these comprise huge expense in contrast to the generic drugs as well as the non-deterrent branded equivalents.

Conclusion: Many challenges are faced throughout the development of abuse-deterrent formulations. These formulations displayed a substantial drop in abuse incidences but it may lead to other modes of abuse, which may prove more harmful for the users.

Keywords: Pain, acute, chronic, overdose, abuse, deterrent.

« Previous Next »
Graphical Abstract

[1]
Loeser, J.D.; Treede, R-D. The Kyoto protocol of IASP basic pain Terminology☆. Pain, 2008, 137(3), 473-477.
[http://dx.doi.org/10.1016/j.pain.2008.04.025] [PMID: 18583048]
[2]
Haanpää, M.; Attal, N.; Backonja, M.; Baron, R.; Bennett, M.; Bouhassira, D.; Cruccu, G.; Hansson, P.; Haythornthwaite, J.A.; Iannetti, G.D.; Jensen, T.S.; Kauppila, T.; Nurmikko, T.J.; Rice, A.S.C.; Rowbotham, M.; Serra, J.; Sommer, C.; Smith, B.H.; Treede, R.D. NeuPSIG guidelines on neuropathic pain assessment. Pain, 2011, 152(1), 14-27.
[http://dx.doi.org/10.1016/j.pain.2010.07.031] [PMID: 20851519]
[3]
Treede, R-D.; Rief, W.; Barke, A.; Aziz, Q.; Bennett, M.I.; Benoliel, R.; Cohen, M.; Evers, S.; Finnerup, N.B.; First, M.B.; Giamberardino, M.A.; Kaasa, S.; Korwisi, B.; Kosek, E.; Lavand’homme, P.; Nicholas, M.; Perrot, S.; Scholz, J.; Schug, S.; Smith, B.H.; Svensson, P.; Vlaeyen, J.W.S.; Wang, S.J. Chronic pain as a symptom or a disease: the IASP Classification of Chronic Pain for the International Classification of Diseases (ICD-11). Pain, 2019, 160(1), 19-27.
[http://dx.doi.org/10.1097/j.pain.0000000000001384] [PMID: 30586067]
[4]
Aydede, M. Defending the IASP definition of pain. Monist, 2017, 100(4), 439-464.
[http://dx.doi.org/10.1093/monist/onx021]
[5]
Macintyre, P.E.; Huxtable, C.A.; Flint, S.L.; Dobbin, M.D. Costs and consequences: a review of discharge opioid prescribing for ongoing management of acute pain. Anaesth. Intens. Care, 2014, 42(5), 558-574.
[http://dx.doi.org/10.1177/0310057X1404200504] [PMID: 25233168]
[6]
Carr, DB; Goudas, LC Acute pain lancet. 1999, 353(9169), 2051-2058.
[7]
Adler, J.A.; Mallick-Searle, T. An overview of abuse-deterrent opioids and recommendations for practical patient care. J. Multidiscip. Healthc., 2018, 11, 323-332.
[http://dx.doi.org/10.2147/JMDH.S166915] [PMID: 30026658]
[8]
Katz, N.P.; Adams, E.H.; Chilcoat, H.; Colucci, R.D.; Comer, S.D.; Goliber, P.; Grudzinskas, C.; Jasinski, D.; Lande, S.D.; Passik, S.D.; Schnoll, S.H.; Sellers, E.; Travers, D.; Weiss, R. Challenges in the development of prescription opioid abuse-deterrent formulations. Clin. J. Pain, 2007, 23(8), 648-660.
[http://dx.doi.org/10.1097/AJP.0b013e318125c5e8] [PMID: 17885342]
[9]
Cicero, T.J.; Ellis, M.S. Abuse-deterrent formulations and the prescription opioid abuse epidemic in the United States: lessons learned from Oxy Contin. JAMA Psychiatry, 2015, 72(5), 424-430.
[http://dx.doi.org/10.1001/jamapsychiatry.2014.3043] [PMID: 25760692]
[10]
Organization WH. WHO guidelines on the pharmacological treatment of persisting pain in children with medical illnesses: World Health Organization. 2012.
[11]
Organization, WH Persisting pain in children package: WHO guidelines on the pharmacological treatment of persisting pain in children with medical illnesses. 2012.
[12]
Cole, B.E. Pain management: classifying, understanding, and treating pain. Hosp. Physician, 2002, 23.
[13]
Orr, P.M.; Shank, B.C.; Black, A.C. The role of pain classification systems in pain management. Critical Care Nursing Clinics., 2017, 29(4), 407-418.
[http://dx.doi.org/10.1016/j.cnc.2017.08.002] [PMID: 29107304]
[14]
Thienhaus, O; Cole, BE Classification of pain. Pain management: A practical guide for clinicians, 2002, 27-36.
[15]
An overview of cancer pain: epidemiology and pathophysiology. Seminars in oncology nursing.
[16]
Pharmacologic management of cancer pain. Seminars in oncology nursing.Elsevier, , 2019.
[17]
Boesch, J.M. Advances in Pain Management: Palliative Care Applications. Vet. Clin. North Am. Small Anim. Pract., 2019, 49(3), 445-461.
[http://dx.doi.org/10.1016/j.cvsm.2019.01.011] [PMID: 30947971]
[18]
Raffa, R.B. Pharmacology of oral combination analgesics: rational therapy for pain. J. Clin. Pharm. Ther., 2001, 26(4), 257-264.
[http://dx.doi.org/10.1046/j.1365-2710.2001.00355.x] [PMID: 11493367]
[19]
Edwards, J.E.; McQuay, H.J.; Moore, R.A. Combination analgesic efficacy: individual patient data meta-analysis of single-dose oral tramadol plus acetaminophen in acute postoperative pain. J. Pain Symptom Manage., 2002, 23(2), 121-130.
[http://dx.doi.org/10.1016/S0885-3924(01)00404-3] [PMID: 11844632]
[20]
Brennan, M.J.; Stanos, S. Strategies to optimize pain management with opioids while minimizing risk of abuse. PM R, 2010, 2(6), 544-558.
[http://dx.doi.org/10.1016/j.pmrj.2010.03.011] [PMID: 20630441]
[21]
Law, J.; Borkan, W.; Ehren, L.; Van Campen, G. Pain management system and method. Google Patents, 1999.
[22]
Tripathi, K. Essentials of medical pharmacology, Jaypee Brothers. Med Pub Ltd New Delhi Edn, 2003, 5(93), 4.
[23]
Witenko, C.; Moorman-Li, R.; Motycka, C.; Duane, K.; Hincapie- Castillo, J.; Leonard, P.; Valaer, C. Considerations for the appropriate use of skeletal muscle relaxants for the management of acute low back pain. P&T, 2014, 39(6), 427-435.
[PMID: 25050056]
[24]
Tremont-Lukats, I.W.; Megeff, C.; Backonja, M-M. Anticonvulsants for neuropathic pain syndromes: mechanisms of action and place in therapy. Drugs, 2000, 60(5), 1029-1052.
[http://dx.doi.org/10.2165/00003495-200060050-00005] [PMID: 11129121]
[25]
Vyvey, M. Steroids as pain relief adjuvants. Can. Fam. Physician, 2010, 56(12), 1295-1297, e415.
[PMID: 21156893]
[26]
Bagshaw, K.R.; Hanenbaum, C.L.; Carbone, E.J.; Lo, K.W.; Laurencin, C.T.; Walker, J.; Nair, L.S. Pain management via local anesthetics and responsive hydrogels. Ther. Deliv., 2015, 6(2), 165-176.
[http://dx.doi.org/10.4155/tde.14.95] [PMID: 25690085]
[27]
Orchard, J.W. Benefits and risks of using local anaesthetic for pain relief to allow early return to play in professional football. Br. J. Sports Med., 2002, 36(3), 209-213.
[http://dx.doi.org/10.1136/bjsm.36.3.209] [PMID: 12055117]
[28]
Sansgiry, S.S.; Bhansali, A.H.; Bapat, S.S.; Xu, Q. Abuse of over-the-counter medicines: a pharmacist’s perspective. Integr. Pharm. Res. Pract., 2017, 6, 1-6.
[http://dx.doi.org/10.2147/IPRP.S103494] [PMID: 29354545]
[29]
McCarthy, M. Prescription drug abuse up sharply in the USA. Lancet, 2007, 369(9572), 1505-1506.
[http://dx.doi.org/10.1016/S0140-6736(07)60690-4] [PMID: 17486697]
[30]
White, D. Discuss patients’ perceptions of treatment to tackle non-adherence. Evaluation, 2020, 15, 13.
[31]
Kelly, B.C.; Rendina, H.J.; Vuolo, M.; Wells, B.E.; Parsons, J.T. Influences of motivational contexts on prescription drug misuse and related drug problems. J. Subst. Abuse Treat., 2015, 48(1), 49-55.
[http://dx.doi.org/10.1016/j.jsat.2014.07.005] [PMID: 25115134]
[32]
Lessenger, J.E.; Feinberg, S.D. Abuse of prescription and over-the-counter medications. J. Am. Board Fam. Med., 2008, 21(1), 45-54.
[http://dx.doi.org/10.3122/jabfm.2008.01.070071] [PMID: 18178702]
[33]
Edlund, M.J.; Steffick, D.; Hudson, T.; Harris, K.M.; Sullivan, M. Risk factors for clinically recognized opioid abuse and dependence among veterans using opioids for chronic non-cancer pain. Pain, 2007, 129(3), 355-362.
[http://dx.doi.org/10.1016/j.pain.2007.02.014] [PMID: 17449178]
[34]
McCabe, S.E.; Boyd, C.J.; Teter, C.J. Subtypes of nonmedical prescription drug misuse. Drug Alcohol Depend., 2009, 102(1-3), 63-70.
[http://dx.doi.org/10.1016/j.drugalcdep.2009.01.007] [PMID: 19278795]
[35]
Akram, G. Over-the-counter medication: an emerging and neglected drug abuse? J. Subst. Use, 2000, 5(2), 136-142.
[http://dx.doi.org/10.3109/14659890009053078]
[36]
Lader, M. Anxiolytic drugs: dependence, addiction and abuse. Eur. Neuropsychopharmacol., 1994, 4(2), 85-91.
[http://dx.doi.org/10.1016/0924-977X(94)90001-9] [PMID: 7919947]
[37]
Cooper, R.J. Over-the-counter medicine abuse - a review of the literature. J. Subst. Use, 2013, 18(2), 82-107.
[http://dx.doi.org/10.3109/14659891.2011.615002] [PMID: 23525509]
[38]
Abuse, S. Mental Health Services Administration Office of Applied Studies: Results from the 2007 National Survey on Drug Use and Health: National Findings (NSDUH Series H-34, DHHS Publication No. SMA 08-4343). Substance Abuse and Mental Health Services Administration, Office of Applied Studies: Rockville, MD, , 2008.
[39]
Hahn, K.L. Strategies to prevent opioid misuse, abuse, and diversion that may also reduce the associated costs. Am. Health Drug Benefits, 2011, 4(2), 107-114.
[PMID: 25126342]
[40]
Hernandez, S.H.; Nelson, L.S. Prescription drug abuse: insight into the epidemic. Clin. Pharmacol. Ther., 2010, 88(3), 307-317.
[http://dx.doi.org/10.1038/clpt.2010.154] [PMID: 20686478]
[41]
Wightman, R.; Perrone, J.; Portelli, I.; Nelson, L. Likeability and abuse liability of commonly prescribed opioids. J. Med. Toxicol., 2012, 8(4), 335-340.
[http://dx.doi.org/10.1007/s13181-012-0263-x] [PMID: 22992943]
[42]
Manchikanti, L.; Singh, A. Therapeutic opioids: a ten-year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids. Pain Physician, 2008, 11(2)(Suppl.), S63-S88.
[http://dx.doi.org/10.36076/ppj.2008/11/S63] [PMID: 18443641]
[43]
Allgulander, C. History and current status of sedative-hypnotic drug use and abuse. Acta Psychiatr. Scand., 1986, 73(5), 465-478.
[http://dx.doi.org/10.1111/j.1600-0447.1986.tb02713.x] [PMID: 2875607]
[44]
Lundqvist, T. Cognitive consequences of cannabis use: comparison with abuse of stimulants and heroin with regard to attention, memory and executive functions. Pharmacol. Biochem. Behav., 2005, 81(2), 319-330.
[http://dx.doi.org/10.1016/j.pbb.2005.02.017] [PMID: 15925403]
[45]
Toomey, R.; Lyons, M.J.; Eisen, S.A.; Xian, H.; Chantarujikapong, S.; Seidman, L.J.; Faraone, S.V.; Tsuang, M.T. A twin study of the neuropsychological consequences of stimulant abuse. Arch. Gen. Psychiatry, 2003, 60(3), 303-310.
[http://dx.doi.org/10.1001/archpsyc.60.3.303] [PMID: 12622664]
[46]
Balhara, Y.P.S.; Jain, R.; Dhawan, A.; Mehta, M. Assessment of abuse liability of pheniramine among opioid-dependent human subjects. J. Subst. Use, 2011, 16(6), 484-495.
[http://dx.doi.org/10.3109/14659891.2010.513753]
[47]
Sapienza, F.L. Abuse deterrent formulations and the Controlled Substances Act (CSA). Drug Alcohol Depend., 2006, 83(Suppl. 1), S23-S30.
[http://dx.doi.org/10.1016/j.drugalcdep.2005.11.028] [PMID: 16529882]
[48]
McCormick, C.G. Regulatory challenges for new formulations of controlled substances in today’s environment. Drug Alcohol Depend., 2006, 83(Suppl. 1), S63-S67.
[http://dx.doi.org/10.1016/j.drugalcdep.2006.02.001] [PMID: 16567060]
[49]
Grudzinskas, C.; Balster, R.L.; Gorodetzky, C.W.; Griffiths, R.R.; Henningfield, J.E.; Johanson, C-E.; Mansbach, R.S.; McCormick, C.G.; Schnoll, S.H.; Strain, E.C.; Wright, C. Impact of formulation on the abuse liability, safety and regulation of medications: the expert panel report. Drug Alcohol Depend., 2006, 83(Suppl. 1), S77-S82.
[http://dx.doi.org/10.1016/j.drugalcdep.2006.02.008] [PMID: 16580154]
[50]
Vaughn, J.; Crowley, M.; Zhang, F.; Koleng, J.; Keen, J.; Hughey, J. Hydrophobic abuse deterrent delivery system. Google Patents, 2008.
[51]
Compton, W.M.; Volkow, N.D. Abuse of prescription drugs and the risk of addiction. Drug Alcohol Depend., 2006, 83(Suppl. 1), S4-S7.
[http://dx.doi.org/10.1016/j.drugalcdep.2005.10.020] [PMID: 16563663]
[52]
Hirsh, J.C.; Fleming, A.B.; Rariy, R.V.; Klibanov, A.M. Abuse-deterrent drug formulations Google Patents, 2010.
[53]
Walter, C.; Knothe, C.; Lötsch, J. Abuse-deterrent opioid formulations: pharmacokinetic and pharmacodynamic considerations. Clin. Pharmacokinet., 2016, 55(7), 751-767.
[http://dx.doi.org/10.1007/s40262-015-0362-3] [PMID: 26719075]
[54]
ICI S. Pan-Canadian Trends in the Prescribing of Opioids,2012 to 2016. 2017.
[55]
Volkow, N.D.; McLellan, A.T. Opioid abuse in chronic pain—misconceptions and mitigation strategies. N. Engl. J. Med., 2016, 374(13), 1253-1263.
[http://dx.doi.org/10.1056/NEJMra1507771] [PMID: 27028915]
[56]
Peacock, A.; Larance, B.; Bruno, R.; Pearson, S-A.; Buckley, N.A.; Farrell, M.; Degenhardt, L. Effectiveness and framing of pharmaceutical opioid abuse-deterrent formulations. Addiction, 2019, 114(3), 404-405.
[http://dx.doi.org/10.1111/add.14556] [PMID: 30767388]
[57]
Peacock, A.; Larance, B.; Bruno, R.; Pearson, S.A.; Buckley, N.A.; Farrell, M.; Degenhardt, L. Post-marketing studies of pharmaceutical opioid abuse-deterrent formulations: a framework for research design and reporting. Addiction, 2019, 114(3), 389-399.
[http://dx.doi.org/10.1111/add.14380] [PMID: 29989247]
[58]
Carter, L.P.; Griffiths, R.R. Principles of laboratory assessment of drug abuse liability and implications for clinical development. Drug Alcohol Depend., 2009, 105(Suppl. 1), S14-S25.
[http://dx.doi.org/10.1016/j.drugalcdep.2009.04.003] [PMID: 19443137]
[59]
Litman, R.S.; Pagán, O.H.; Cicero, T.J. Abuse-deterrent opioid formulations. Anesthesiology. Anesthesiology, 2018, 128(5), 1015-1026.
[http://dx.doi.org/10.1097/ALN.0000000000002031] [PMID: 29252508]
[60]
Webster, L. Update on abuse-resistant and abuse-deterrent approaches to opioid formulations. Pain Med., 2009, 10(Suppl. 2), S124-S133.
[http://dx.doi.org/10.1111/j.1526-4637.2009.00672.x] [PMID: 19691683]
[61]
Simon, K.; Worthy, S.L.; Barnes, M.C.; Tarbell, B. Abuse-deterrent formulations: transitioning the pharmaceutical market to improve public health and safety. Ther. Adv. Drug Saf., 2015, 6(2), 67-79.
[http://dx.doi.org/10.1177/2042098615569726] [PMID: 25922655]
[62]
Romach, M.K.; Schoedel, K.A.; Sellers, E.M. Update on tamper-resistant drug formulations. Drug Alcohol Depend., 2013, 130(1-3), 13-23.
[http://dx.doi.org/10.1016/j.drugalcdep.2012.12.028] [PMID: 23415386]
[63]
Maincent, J.; Zhang, F. Recent advances in abuse-deterrent technologies for the delivery of opioids. Int. J. Pharm., 2016, 510(1), 57-72.
[http://dx.doi.org/10.1016/j.ijpharm.2016.06.012] [PMID: 27291971]
[64]
Xu, X.; Gupta, A.; Al-Ghabeish, M.; Calderon, S.N.; Khan, M.A. Risk based in vitro performance assessment of extended release abuse deterrent formulations. Int. J. Pharm., 2016, 500(1-2), 255-267.
[http://dx.doi.org/10.1016/j.ijpharm.2016.01.031] [PMID: 26784976]
[65]
Alexander, L.; Mannion, R.O.; Weingarten, B.; Fanelli, R.J.; Stiles, G.L. Development and impact of prescription opioid abuse deterrent formulation technologies. Drug Alcohol Depend., 2014, 138, 1-6.
[http://dx.doi.org/10.1016/j.drugalcdep.2014.02.006] [PMID: 24613631]
[66]
Mastropietro, D.J.; Omidian, H. Abuse-deterrent formulations: part 1 - development of a formulation-based classification system. Expert Opin. Drug Metab. Toxicol., 2015, 11(2), 193-204.
[http://dx.doi.org/10.1517/17425255.2015.979786] [PMID: 25374404]
[67]
Hale, M.E.; Moe, D.; Bond, M.; Gasior, M.; Malamut, R. Abuse-deterrent formulations of prescription opioid analgesics in the management of chronic noncancer pain. Pain Manag. (Lond.), 2016, 6(5), 497-508.
[http://dx.doi.org/10.2217/pmt-2015-0005] [PMID: 27050830]
[68]
Cohen, J.P.; Mendoza, M.; Roland, C. Challenges involved in the development and delivery of abuse-deterrent formulations of opioid analgesics. Clin. Ther., 2018, 40(2), 334-344.
[http://dx.doi.org/10.1016/j.clinthera.2018.01.003] [PMID: 29398162]
[69]
Joshi, Y.; Muppalaneni, S.; Omidian, A.; Mastropietro, D.J.; Omidian, H. Determining Abuse Deterrence Performance of Poly (ethylene oxide) Using a Factorial Design. Adv. Pharm. Bull., 2018, 8(3), 495-505.
[http://dx.doi.org/10.15171/apb.2018.058] [PMID: 30276147]
[70]
Cicero, T.J.; Ellis, M.S.; Surratt, H.L. Effect of abuse-deterrent formulation of OxyContin. N. Engl. J. Med., 2012, 367(2), 187-189.
[http://dx.doi.org/10.1056/NEJMc1204141] [PMID: 22784140]
[71]
Nalamachu, S.R.; Kutch, M.; Hale, M.E. Safety and Tolerability of Once-Daily OROS(®) hydromorphone extended-release in opioid-tolerant adults with moderate-to-severe chronic cancer and noncancer pain: pooled analysis of 11 clinical studies. J. Pain Symptom Manage., 2012, 44(6), 852-865.
[http://dx.doi.org/10.1016/j.jpainsymman.2011.12.280] [PMID: 22795050]
[72]
Craig, D.S. Oxymorphone extended-release tablets (Opana ER) for the management of chronic pain: a practical review for pharmacists. P&T, 2010, 35(6), 324-357.
[PMID: 20592876]
[73]
Setnik, B.; Roland, C.L.; Cleveland, J.M.; Webster, L. The abuse potential of Remoxy(®), an extended-release formulation of oxycodone, compared with immediate- and extended-release oxycodone. Pain Med., 2011, 12(4), 618-631.
[http://dx.doi.org/10.1111/j.1526-4637.2011.01093.x] [PMID: 21463474]
[74]
Mastropietro, D.J.; Omidian, H. Current approaches in tamper-resistant and abuse-deterrent formulations. Drug Dev. Ind. Pharm., 2013, 39(5), 611-624.
[http://dx.doi.org/10.3109/03639045.2012.680468] [PMID: 22537282]
[75]
Marnoor, S.A. Abuse deterrent opioid formulations: a review. Res. J. Pharm. Dos. Forms Technol., 2016, 8(2), 135-140.
[http://dx.doi.org/10.5958/0975-4377.2016.00018.5]
[76]
Stinchcomb, A.L.; Li, G.; Banks, S.L.; Howard, J.L.; Golinski, M.J. Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists. Google Patents, 2013.
[77]
Schaeffer, T. Abuse-deterrent formulations, an evolving technology against the abuse and misuse of opioid analgesics. J. Med. Toxicol., 2012, 8(4), 400-407.
[http://dx.doi.org/10.1007/s13181-012-0270-y] [PMID: 23073726]
[78]
Baxi, V. Management of acute pain. J. Assoc. Physicians India, 2015, 63(2)(Suppl.), 14-20.
[PMID: 26529854]
[79]
Management of common adverse events in patients treated with sorafenib: nurse and pharmacist perspective. Seminars in oncology.Elsevier, , 2014.
[80]
Dang, M. A Summary of Newer and Safer Opioid Formulations. Curr. Anesthesiol. Rep., 2018, 8(4), 337-341.
[http://dx.doi.org/10.1007/s40140-018-0290-5]
[81]
Jasinski, D.R.; Krishnan, S. Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers. J. Psychopharmacol., 2009, 23(4), 410-418.
[http://dx.doi.org/10.1177/0269881108093841] [PMID: 18635707]
[82]
Cassidy, T.A.; DasMahapatra, P.; Black, R.A.; Wieman, M.S.; Butler, S.F. Changes in prevalence of prescription opioid abuse after introduction of an abuse-deterrent opioid formulation. Pain Med., 2014, 15(3), 440-451.
[http://dx.doi.org/10.1111/pme.12295] [PMID: 24330279]
[83]
Strategies to reduce the tampering and subsequent abuse of long-acting opioids: potential risks and benefits of formulations with physical or pharmacologic deterrents to tampering. Mayo Clinic Proceedings. Stanos, S.P.; Bruckenthal, P.; Barkin, R.L., Eds.; Elsevier,. , 2012.
[84]
Moorman-Li, R.; Motycka, C.A.; Inge, L.D.; Congdon, J.M.; Hobson, S.; Pokropski, B. A review of abuse-deterrent opioids for chronic nonmalignant pain. P&T, 2012, 37(7), 412-418.
[PMID: 22876107]
[85]
Hull, M.J.; Bierer, M.F.; Griggs, D.A.; Long, W.H.; Nixon, A.L.; Flood, J.G. Urinary buprenorphine concentrations in patients treated with suboxone as determined by liquid chromatography-mass spectrometry and CEDIA immunoassay. J. Anal. Toxicol., 2008, 32(7), 516-521.
[http://dx.doi.org/10.1093/jat/32.7.516] [PMID: 18713521]
[86]
Singer, J.A. Abuse‐ Deterrent Opioids and the Law of Unintended Consequences. Cato Institute Policy Analysis, 2018, 832.
[87]
Ruan, X.; Chen, T.; Gudin, J.; Couch, J.P.; Chiravuri, S. Acute opioid withdrawal precipitated by ingestion of crushed embeda (morphine extended release with sequestered naltrexone): case report and the focused review of the literature. J. Opioid. Manag., 2010, 6(4), 300-303.
[http://dx.doi.org/10.5055/jom.2010.0028] [PMID: 20862910]
[88]
Eisenhauer, T.D.; Matchett, M.; Heasley, R.; Morton, T.; Devarakonda, K.; Giuliani, M.; Young, J.L.; Barrett, T. Evaluation of the tamper-resistant properties of biphasic immediate-release/extended-release oxycodone/acetaminophen tablets. Drug Dev. Ind. Pharm., 2016, 42(1), 157-165.
[http://dx.doi.org/10.3109/03639045.2015.1038272] [PMID: 26146769]
[89]
Reinhart, M.; Scarpati, L.M.; Kirson, N.Y.; Patton, C.; Shak, N.; Erensen, J.G. The economic burden of abuse of prescription opioids: a systematic literature review from 2012 to 2017. Appl. Health Econ. Health Policy, 2018, 16(5), 609-632.
[http://dx.doi.org/10.1007/s40258-018-0402-x] [PMID: 30027533]
[90]
Opioids, A-D. Evaluation and Labeling Guidance for Industry. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Clin. Med. (Lond.), 2015.
[91]
Cone, E.J.; Giordano, J.; Weingarten, B. An iterative model for in vitro laboratory assessment of tamper deterrent formulations. Drug Alcohol Depend., 2013, 131(1-2), 100-105.
[http://dx.doi.org/10.1016/j.drugalcdep.2012.12.006] [PMID: 23332441]
[92]
Pappagallo, M.; Sokolowska, M. The implications of tamper-resistant formulations for opioid rotation. Postgrad. Med., 2012, 124(5), 101-109.
[http://dx.doi.org/10.3810/pgm.2012.09.2588] [PMID: 23095430]
[93]
Boyce, H.; Smith, D.; Byrn, S.; Saluja, B.; Qu, W.; Gurvich, V.J.; Hoag, S.W. In vitro assessment of nasal insufflation of comminuted drug products designed as abuse deterrent using the vertical diffusion cell. AAPS Pharm. Sci. Tech., 2018, 19(4), 1744-1757.
[http://dx.doi.org/10.1208/s12249-017-0947-2] [PMID: 29582347]
[94]
Khan, M.F.; Gharibo, C. Abuse deterrent opioids. Tech. Reg. Anesth. Pain Manage., 2010, 14(2), 99-103.
[http://dx.doi.org/10.1053/j.trap.2010.03.006]
[95]
Brooks, A.; Kominek, C. ADF: Abuse-Deterrent Formulation or Another Disillusioned Formulation? Oxford University Press, 2018.
[96]
Bannwarth, B. Will abuse-deterrent formulations of opioid analgesics be successful in achieving their purpose? Drugs, 2012, 72(13), 1713-1723.
[http://dx.doi.org/10.2165/11635860-000000000-00000] [PMID: 22931520]
[97]
Dart, R.C.; Surratt, H.L.; Cicero, T.J.; Parrino, M.W.; Severtson, S.G.; Bucher-Bartelson, B.; Green, J.L. Trends in opioid analgesic abuse and mortality in the United States. N. Engl. J. Med., 2015, 372(3), 241-248.
[http://dx.doi.org/10.1056/NEJMsa1406143] [PMID: 25587948]
[98]
Lee, Y.H.; Brown, D.L.; Chen, H.Y. Current impact and application of abuse-deterrent opioid formulations in clinical practice. Pain Phys., 2017, 20(7), E1003-E1023.
[PMID: 29149148]
[99]
Rahman, Z; Dharani, S; Charoo, NA; Nutan, MT; Khan, MA Drug Abuse: Addiction and Recovery.
[100]
Food, Administration D. FDA requests removal of Opana ER for risks related to abuse. 2017.
[101]
Kaufman, M.B. The Risks of Opana Extended Release.
[102]
Lourenço, L.M.; Matthews, M.; Jamison, R.N. Abuse-deterrent and tamper-resistant opioids: how valuable are novel formulations in thwarting non-medical use? Expert Opin Drug Deliv., 2013, 10(2), 229-240.
[http://dx.doi.org/10.1517/17425247.2013.751095] [PMID: 23252692]
[103]
Schoedel, K.A.; McMorn, S.; Chakraborty, B.; Potts, S.L.; Zerbe, K.; Sellers, E.M. Positive and negative subjective effects of extended-release oxymorphone versus controlled-release oxycodone in recreational opioid users. J. Opioid Management, 2011, 7(3), 179-192.
[http://dx.doi.org/10.5055/jom.2011.0061] [PMID: 21823549]
[104]
Budman, S.H.; Grimes Serrano, J.M.; Butler, S.F. Can abuse deterrent formulations make a difference? Expectation and speculation. Harm Reduction J., 2009, 6(1), 8.
[http://dx.doi.org/10.1186/1477-7517-6-8] [PMID: 19480676]

Rights & Permissions Print Cite
Article Metrics
21
1
© 2024 Bentham Science Publishers | Privacy Policy